All about implementing Microchips in Humans

Discussion in 'Off Topic' started by Dr. AMK, Jul 25, 2017.

  1. custom90gt

    custom90gt Doc Mod Super Moderator

    Reputations:
    7,363
    Messages:
    3,339
    Likes Received:
    3,602
    Trophy Points:
    331
    Bump, reopened per request
     
    Dr. AMK likes this.
  2. Dr. AMK

    Dr. AMK Living with Hope

    Reputations:
    3,066
    Messages:
    1,938
    Likes Received:
    4,123
    Trophy Points:
    281
    Thank you for your kindness.
     
    hmscott likes this.
  3. Dr. AMK

    Dr. AMK Living with Hope

    Reputations:
    3,066
    Messages:
    1,938
    Likes Received:
    4,123
    Trophy Points:
    281
    Amazon’s Pay By Hand: Why the Biometric Push is a Red Flag
    January 20, 2020
    https://harbingersdaily.com/amazon-pay-by-hand/

    "At one time, the idea that large numbers of people would willingly allow themselves to have microchips implanted into their hands seemed a bit crazy, but now it has become a reality."
    [​IMG]
    If anyone has the power, money and influence to persuade people to accept a new form of payment systems for commerce, it is Amazon.
     
    hmscott likes this.
  4. Dr. AMK

    Dr. AMK Living with Hope

    Reputations:
    3,066
    Messages:
    1,938
    Likes Received:
    4,123
    Trophy Points:
    281
    hmscott likes this.
  5. Dr. AMK

    Dr. AMK Living with Hope

    Reputations:
    3,066
    Messages:
    1,938
    Likes Received:
    4,123
    Trophy Points:
    281
  6. hmscott

    hmscott Notebook Nobel Laureate

    Reputations:
    7,072
    Messages:
    20,418
    Likes Received:
    25,218
    Trophy Points:
    931
    BIOchip's have many uses, not just privacy invading identification and tracking: here's a promising array multiplex biochip of timely importance:

    Randox unveils new coronavirus test at Medlab Middle East 2020
    LABline, Feb 7th, 2020
    https://www.mlo-online.com/disease/...w-coronavirus-test-at-medlab-middle-east-2020

    "A ground-breaking test for the potentially fatal 2019-nCoV strain of coronavirus, is in the final stages of development at global health diagnostics company Randox Laboratories.

    The soon-to-be-launched test, developed on Randox’s patented Biochip Technology, will be available for immediate 2019-nCoV testing, but an additional enhanced multiplex array will also include tests for other respiratory viruses which can display the same symptoms.

    The new enhanced Biochip will therefore allow clinicians to quickly and efficiently differentiate between potentially lethal and non-lethal infections.

    The test will be available for the POC analyzer, the Vivalytic, within three hours, and within five hours on the Randox Evidence Investigator.

    Benefits of the new Randox 2019-nCoV test

    • Quick turnaround times (three hours on Vivalytic and five hours on Evidence Investigator)

    • Multiplex array differentiates between mild and serious infection

    • Automated and semi-automated options available

    Visit Randox for more news"

    Introducing the 2019-nCoV Coronavirus Test from Randox
    https://www.randox.com/coronavirus-randox-test

    "A ground-breaking test for the potentially fatal 2019-nCoV strain of coronavirus, is in the final stages of development at global health diagnostics company Randox Laboratories.

    The soon-to-be-launched test, developed on Randox’s patented Biochip Technology, will be available for immediate 2019-nCoV testing, but an additional enhanced multiplex array will also include tests for other respiratory viruses which can display the same symptoms.

    The new enhanced Biochip will therefore allow clinicians to quickly and efficiently differentiate between potentially lethal and non-lethal infections.

    Dr Peter FitzGerald, Managing Director of Randox Laboratories, commented;

    “Current technologies for the diagnosis of coronavirus are designed simply to detect the presence or lack of 2019-nCoV, and therefore neglect to differentiate between this strain and other respiratory infections.

    “Whilst we’re very quickly developing an efficient novel test for this new strain of coronavirus, we are therefore also working on an extended Viral Respiratory Infection Array that will test simultaneously for 2019-nCoV and a range of other viruses. This will eliminate the need for multiple back-and-forth tests before the root cause of symptoms is found, and empower clinicians to make fast and informed decisions.”

    The test will be available for the Point of Care analyser, the Vivalytic, within 3 hours, and within 5 hours on the Randox Evidence Investigator.

    Benefits of the new Randox 2019-nCoV test
    • Quick Turnaround Times (3 hours on Vivalytic and 5 hours on Evidence Investigator)
    • Multiplex array differentiates between mild and serious infection
    • Automated and Semi-Automated options available
    Randox also currently has available a Respiratory Tract Infection Array, which can test for 22 viral and bacterial respiratory infections simultaneously. The test therefore determines the exact cause of your symptoms and differentiates between mild and serious infections, such as coronavirus. This is also available from Randox Health as a Cold, Cough and Flu test.

    For further information please visit www.randox.com/coronavirus-randox

    For enquiries email marketing@randox.com or to book your Randox Health Cough, Cold and Flu test please ring 0800 2545 130.

    Randox is committed to saving and improving lives on a global scale, and will bring you updates on developments on our test for 2019-nCoV as and when they happen."
     
    Last edited: Feb 12, 2020
    Dr. AMK likes this.

Share This Page